Patents Assigned to U3 Pharma GmbH
-
Publication number: 20240043939Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.Type: ApplicationFiled: October 13, 2023Publication date: February 8, 2024Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, Amgen, Inc.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
-
Patent number: 11840736Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.Type: GrantFiled: August 21, 2019Date of Patent: December 12, 2023Assignees: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, Amgen, Inc.Inventors: Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin
-
Publication number: 20200140954Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.Type: ApplicationFiled: August 21, 2019Publication date: May 7, 2020Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, INC.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
-
Publication number: 20200115467Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.Type: ApplicationFiled: August 21, 2019Publication date: April 16, 2020Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
-
Publication number: 20170166654Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.Type: ApplicationFiled: October 19, 2016Publication date: June 15, 2017Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
-
Publication number: 20170166973Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.Type: ApplicationFiled: October 19, 2016Publication date: June 15, 2017Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, Inc.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
-
Publication number: 20170021031Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).Type: ApplicationFiled: October 4, 2016Publication date: January 26, 2017Applicants: DAIICHI SANKYO COMPANY, LIMITED, U3 PHARMA GMBHInventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
-
Publication number: 20160222126Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.Type: ApplicationFiled: January 18, 2016Publication date: August 4, 2016Applicants: U3 PHARMA GMBH, AMGEN, INC.Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
-
Publication number: 20160168264Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: ApplicationFiled: December 15, 2015Publication date: June 16, 2016Applicants: U3 PHARMA GMBH, AMGEN, INC.Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, SUSANNE HARTMANN, LARRY L. GREEN
-
Publication number: 20160161491Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.Type: ApplicationFiled: February 18, 2016Publication date: June 9, 2016Applicant: U3 PHARMA GMBHInventors: Mike ROTHE, Martin TREDER
-
Patent number: 9284379Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.Type: GrantFiled: January 18, 2013Date of Patent: March 15, 2016Assignee: U3 Pharma GmbHInventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
-
Patent number: 9249230Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: GrantFiled: February 4, 2009Date of Patent: February 2, 2016Assignees: U3 Pharma GmbH, Amgen Inc.Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
-
Patent number: 9101760Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.Type: GrantFiled: November 12, 2010Date of Patent: August 11, 2015Assignees: U3 Pharma GmbH, Amgen, Inc.Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
-
Publication number: 20150152508Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.Type: ApplicationFiled: September 30, 2014Publication date: June 4, 2015Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbHInventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
-
Publication number: 20150152193Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: December 8, 2014Publication date: June 4, 2015Applicant: U3 PHARMA GMBHInventors: Thore HETTMANN, Jens NIEWOEHNER, Jens RUHE, Peter WIRTZ, Kerstin SELLE, Esther ZWICK-WALLASCH, Mike ROTHE
-
Publication number: 20150147326Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.Type: ApplicationFiled: September 30, 2014Publication date: May 28, 2015Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki UniversityInventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
-
Publication number: 20150037336Abstract: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.Type: ApplicationFiled: February 20, 2013Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventor: Esther Zwick Wallasch
-
Publication number: 20150037323Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventors: Peter WIRTZ, Jens RUHE, Takeshi TAKIZAWA, Tomoko TAKAYAMA
-
Patent number: 8933202Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: GrantFiled: November 12, 2008Date of Patent: January 13, 2015Assignee: U3 Pharma GmbHInventors: Thore Hettmann, Jens Niewöhner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
-
Patent number: 8841424Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: GrantFiled: May 11, 2010Date of Patent: September 23, 2014Assignee: U3 Pharma GmbHInventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama